TherapeuticsMD
TXMD
160 hedge funds and large institutions have $237M invested in TherapeuticsMD in 2021 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 62 increasing their positions, 27 reducing their positions, and 24 closing their positions.
130% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 27
66% more call options, than puts
Call options by funds: $2.56M | Put options by funds: $1.54M
20% more capital invested
Capital invested by funds: $197M → $237M (+$39.9M)
13% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 24
1% more funds holding
Funds holding: 159 → 160 (+1)
0.17% less ownership
Funds ownership: 1.09% → 0.91% (-0.17%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$9.67M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.71M |
| 3 |
State Street
Boston,
Massachusetts
|
+$4.31M |
| 4 |
PA
Perceptive Advisors
New York
|
+$4.31M |
| 5 |
Millennium Management
New York
|
+$3.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GC
GMT Capital
Atlanta,
Georgia
|
-$7.24M |
| 2 |
Handelsbanken Fonder
Stockholm,
Sweden
|
-$3.92M |
| 3 |
Morgan Stanley
New York
|
-$3.07M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$2.7M |
| 5 |
HI
Handelsinvest Investeringsforvaltning
Herning,
Denmark
|
-$1.45M |
TXMD Hedge Fund Activity: Q1 2021 in Review
160 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in TherapeuticsMD (TXMD) for Q1 2021, worth a combined $237M — up 20% from $197M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new TXMD positions and 24 closed out — a net gain of 3 holders — while 62 added to existing stakes and 27 trimmed.
The largest buyer was BlackRock, adding an estimated $9.67M. The largest seller was GMT Capital, exiting entirely with an estimated $7.24M sold.
- 160 institutional investors held TherapeuticsMD (TXMD) as of Q1 2021, up from 159 in Q4 2020.
- Funds reported $237M of TherapeuticsMD stock for Q1 2021, up 20% quarter-over-quarter.
- 27 funds opened new TherapeuticsMD positions in Q1 2021 and 24 closed out, a net change of +3 holders.
- The largest TherapeuticsMD buyer in Q1 2021 was BlackRock, an estimated $9.67M added.
- The largest TherapeuticsMD seller in Q1 2021 was GMT Capital, an estimated $7.24M sold.
Based on aggregated 13F filings for Q1 2021.